Personalized Cancer Vaccines Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — built from company filings, government statistics and trade data, and structured for confident strategic decision-making. Request a free report preview to see its scope, chapters and methodology before you buy.
Market Snapshot
2025 Market Size
US$ 416.0 million
Estimated Base Value
2035 Forecast
US$ 5.3 billion
Projected Market Value
CAGR 2026–2035
29.0%
Compound Annual Growth
Largest Segment
Neoantigen-based Vaccines
Fastest Growing Segment
Electric Commercial Vehicles
Leading Region
North America
Fastest Growing Region
Asia Pacific
Top Country
United States
By Market Share
Largest market
Key Players
BioNTech
Emerging Players
Moderna, Nykode Therapeutics
Personalized Cancer Vaccines Market Overview
The Personalized Cancer Vaccines Market focuses on the development and commercialization of therapeutic biologic drugs tailored to an individual patient's unique tumor genetic profile. These vaccines stimulate the patient's immune system to identify and attack cancer cells by targeting specific neoantigens present only on their tumor. This market leverages advanced genomic sequencing and bioinformatics to create individualized immune responses across various cancer types, aiming to prevent recurrence or treat advanced malignancies. Key buyers include hospitals, specialty oncology clinics, and academic research centers seeking precision oncology solutions.
The global Personalized Cancer Vaccines Market is estimated at $416.0 Mn in 2025 and is forecast to reach $5.3 Bn by 2035, exhibiting a CAGR of 29.0% from 2025 to 2035. This growth is driven by the increasing global incidence of cancer and the significant unmet medical need in various advanced cancers. Advancements in genomic sequencing and neoantigen prediction also fuel demand. However, high manufacturing costs, complex production processes, stringent regulatory pathways, and reimbursement uncertainties act as restraints.
The market is segmented by Type (Neoantigen-Based Vaccines, Autologous Dendritic Cell Vaccines, Mrna Personalized Vaccines, DNA Personalized Vaccines, Viral Vector Personalized Vaccines, Peptide Personalized Vaccines), Technology Platform (Next-Generation Sequencing, Bioinformatics & Artificial Intelligence, CRISPR Gene Editing, Antigen Prediction Algorithms, Mrna Synthesis Platforms, Viral Vector Manufacturing, Cell Culture & Expansion Technologies), Application (Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Pancreatic Cancer, Head & Neck Cancer, Glioblastoma, Others), End-User (Hospitals, Specialty Oncology Clinics, Academic Research Centers), Stage of Development (Preclinical Development, Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, Commercialized Products), and Form (Injectable Solutions, Lyophilized Formulations, Cellular Suspensions). Leading companies include BioNTech, Gritstone bio, CureVac, Agenus, Transgene, PDS Biotechnology, Nouscom, Evaxion Biotech, Biond Biologics, Elios Therapeutics, Capella Bioscience, and NeoCura. The full report covers global market analysis across key regions and countries, segmentation by cancer type, technology platform, and patient population, along with market sizing and forecast from 2025 to 2035.
Market Definition & Overview
The Personalized Cancer Vaccines Market involves the research, development, manufacturing, and commercialization of therapeutic biologic drugs precisely engineered to an individual patient's unique tumor genetic profile. These vaccines stimulate the patient's immune system to identify and attack cancer cells by targeting specific neoantigens present only on their tumor. Leveraging advanced genomic sequencing and bioinformatics, this market focuses on creating highly individualized immune responses across various cancer types, aiming to prevent recurrence or treat advanced malignancies. It encompasses diverse technology platforms, including mRNA, DNA, peptide, and viral vector-based approaches, representing a cutting-edge segment within precision oncology and the biologic drugs industry.
Scope
- Global market analysis across key regions and countries.
- Segmentation by cancer type, technology platform, and patient population.
- Market sizing and forecast from 2025 to 2035.
Inclusions
- Neoantigen-targeted personalized cancer vaccines.
- mRNA, DNA, peptide, and viral vector-based vaccine platforms.
- Autologous and allogeneic personalized vaccine approaches.
- Research, development, and clinical trial activities for personalized cancer vaccines.
- Manufacturing and commercialization of personalized cancer vaccine products.
- Companion diagnostics specifically for neoantigen identification in personalized vaccines.
Exclusions
- Universal or off-the-shelf cancer vaccines not personalized to individual patients.
- Other cancer immunotherapies such as checkpoint inhibitors or CAR-T cell therapies.
- Prophylactic vaccines for infectious diseases or other non-cancer indications.
- Traditional cancer treatments like chemotherapy, radiation therapy, or surgery.
- General vaccine development services not specific to personalized cancer vaccines.
Market Size Forecast
Executive Summary
• The Personalized Cancer Vaccines market is valued at $416.0 Mn in 2025 and is forecast to reach $5.3 Bn by 2035, reflecting a robust CAGR of 29.0% as demand accelerates across every major segment and region over the ten-year outlook.
• Neoantigen-based Vaccines leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at XX.X%, while Emerging Areas is expanding the fastest at a XX.X% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at XX.X% of global share, anchoring overall demand within its home region throughout the forecast period.
• The nascent competitive landscape is rapidly consolidating around strategic alliances and targeted M&A, as big pharma seeks to acquire innovative mRNA and neoantigen platform technologies from agile biotech startups, accelerating market entry and pipeline diversification.
• Breakthroughs in next-generation sequencing and AI-driven neoantigen prediction are significantly de-risking development, propelling personalized vaccine efficacy and patient stratification, thereby unlocking substantial market expansion opportunities across diverse solid tumors.
• Evolving adaptive regulatory pathways, particularly in advanced economies, are streamlining clinical trials and accelerating approvals, fostering regional innovation hubs while posing unique market access and reimbursement challenges globally.
• Significant investment in scalable, decentralized manufacturing and sophisticated logistical cold chain solutions is critical, addressing bespoke production complexities and ensuring timely patient-specific vaccine delivery for widespread adoption.
• The market's long-term growth is heavily contingent on successful combination therapies with checkpoint inhibitors, amplifying clinical outcomes and expanding treatable patient populations beyond current monotherapy indications.
• Strategic shifts towards preventive applications in high-risk populations, alongside therapeutic interventions, represent a pivotal future growth vector requiring substantial, sustained R&D investment and novel clinical trial designs.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Value
The Personalized Cancer Vaccines Market was valued at $416.0 million in the base year, reflecting its emerging but significant position in pharmaceuticals.
Robust Growth Outlook
The market is projected to experience substantial expansion, driven by a strong Compound Annual Growth Rate (CAGR) of 29.0% through the forecast period.
Future Market Potential
By the forecast year, the Personalized Cancer Vaccines Market is expected to reach an impressive $5.3 billion, indicating significant future adoption and investment.
North American Leadership
North America is anticipated to emerge as a leading region in the personalized cancer vaccines market, fueled by advanced research infrastructure and substantial healthcare investments.
Advancing Technological Trend
A notable trend is the continuous advancement in genomic sequencing and bioinformatics, which is crucial for developing highly individualized vaccine candidates and driving market innovation.
Expanding Clinical Pipeline
The increasing number of personalized cancer vaccine candidates progressing through various stages of clinical trials underscores the growing industry focus and potential for future product launches.
Market Dynamics
Market Trends
- mRNA and neoantigen-specific vaccine platforms are gaining traction.
- Accelerating clinical trials across diverse cancer indications is evident.
- AI and machine learning adoption for target identification is rising.
- Strategic partnerships between industry and academia are increasing.
Growth Drivers
- Increasing global cancer incidence drives demand for novel therapies.
- Significant unmet medical need exists in various advanced cancers.
- Advancements in genomic sequencing and neoantigen prediction fuel growth.
- Growing investment and funding in oncology R&D boosts the market.
Restraints
- High manufacturing costs and complex production processes limit widespread adoption.
- Stringent regulatory pathways and lengthy approval times impede market entry.
- Challenges in identifying specific neoantigens accurately hinder development.
- Reimbursement uncertainties and high price points pose significant market barriers.
Opportunities
- Expanding vaccine applications to a broader range of solid tumors.
- Developing combination therapies with existing checkpoint inhibitors.
- Optimizing manufacturing processes for enhanced cost-effectiveness and scalability.
- Tapping into emerging markets with growing healthcare infrastructure offers potential.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Neoantigen-Based VaccinesAutologous Dendritic Cell VaccinesMrna Personalized VaccinesDNA Personalized VaccinesViral Vector Personalized VaccinesPeptide Personalized Vaccines |
| By Technology Platform | Next-Generation SequencingBioinformatics & Artificial IntelligenceCRISPR Gene EditingAntigen Prediction AlgorithmsMrna Synthesis PlatformsViral Vector ManufacturingCell Culture & Expansion Technologies |
| By Application | MelanomaNon-Small Cell Lung CancerColorectal CancerBreast CancerPancreatic CancerHead & Neck CancerGlioblastomaOthers |
| By End-User | HospitalsSpecialty Oncology ClinicsAcademic Research Centers |
| By Stage of Development | Preclinical DevelopmentPhase I Clinical TrialsPhase II Clinical TrialsPhase III Clinical TrialsCommercialized Products |
| By Form | Injectable SolutionsLyophilized FormulationsCellular Suspensions |
Regional Analysis
- North America leads the personalized cancer vaccines market due to substantial R&D investments, a strong presence of key biopharmaceutical companies, and a well-established healthcare infrastructure. Favorable regulatory policies and high cancer incidence rates further drive its dominant position.
- The Asia-Pacific region is poised for the fastest growth, driven by increasing healthcare spending, a rising burden of cancer cases, and enhanced awareness regarding advanced therapies. Government support for biotech innovation and expanding clinical research capabilities also contribute significantly.
- A noteworthy trend in Europe is the increased emphasis on pan-European collaborative research initiatives and public-private partnerships for personalized cancer vaccine development. This collaborative ecosystem aims to accelerate clinical trials and facilitate broader market access across diverse healthcare systems.
| North AmericaXX.X% | EuropeXX.X% | Asia PacificXX.X% | Latin AmericaXX.X% | Middle East & AfricaXX.X% |
North America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Dominates the market due to robust R&D, significant investment in biotech, high incidence of cancer, and early adoption of advanced therapies and clinical trials.
Latin America
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Characterized by emerging economic development and improving healthcare access, though market growth faces challenges in regulatory harmonization and healthcare affordability across the diverse region.
Europe
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Represents a substantial market share with significant research activity and a strong regulatory framework, fueled by an aging population and government support for innovative cancer treatments.
Asia Pacific
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- Exhibits rapid growth potential driven by increasing healthcare expenditure, a large patient population, improving medical infrastructure, and growing awareness of personalized medicine across key economies like China, Japan, and India.
Middle East & Africa
XX.X% CAGR
US$ XX.X Mn
XX.X% share
- A nascent market with growth driven by increasing healthcare investments, rising cancer incidence, and developing medical infrastructure, particularly in affluent Gulf Cooperation Council (GCC) countries.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | US$ XX.X Mn | XX.X% | The U.S. leads in personalized cancer vaccines due to its robust biotech R&D ecosystem, significant healthcare spending, and a high incidence of various cancers. It benefits from advanced regulatory frameworks that support innovative therapeutic development and strong investment in precision medicine. |
| 2 | Brazil | US$ XX.X Mn | XX.X% | As Latin America's largest economy, Brazil presents a substantial patient population and a growing private healthcare sector investing in advanced therapies. The increasing prevalence of cancer and a developing biotech landscape drive demand for personalized vaccines. |
| 3 | Germany | US$ XX.X Mn | XX.X% | Germany boasts Europe's largest pharmaceutical market, supported by robust R&D, high healthcare spending, and a strong focus on precision oncology. Its advanced healthcare system and significant biotech investment make it a key market for innovative cancer therapies. |
| 4 | China | US$ XX.X Mn | XX.X% | China represents a massive patient population with rapidly growing healthcare spending and significant government investment in biotech and precision medicine. Its expanding R&D capabilities and increasing clinical trials are driving the personalized cancer vaccine market. |
| 5 | Saudi Arabia | US$ XX.X Mn | XX.X% | Saudi Arabia demonstrates high healthcare spending and significant investment in advanced medical technologies, driven by a growing private healthcare sector. Its increasing focus on specialized cancer care boosts the adoption of personalized vaccine treatments. |
Countries Covered (27)
United States, Canada, Mexico, Brazil, Argentina, Rest of Latin America, Germany, United Kingdom, France, Switzerland, Italy, Spain, Russia, Rest of Europe, China, Japan, South Korea, India, Australia, Taiwan, Singapore, Malaysia, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, South Africa, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | BioNTech | XX.X% | Leverage proprietary mRNA technology and AI-driven platforms to develop highly individualized immunotherapies and vaccines across oncology and infectious diseases. | — | — | ComirnatyBNT111BNT321+1 |
| 2 | Gritstone bio | XX.X% | Utilize a proprietary AI-driven platform to identify tumor-specific neoantigens and develop personalized RNA-based and adenoviral-based immunotherapies. | — | — | SLATEGRANITECORAL |
| 3 | CureVac | XX.X% | Focus on developing a new generation of mRNA-based medicines, particularly non-modified mRNA, for vaccines and immunotherapies, aiming for improved safety and efficacy profiles. | — | — | CV8102CV0501CV7202 |
| 4 | Agenus | XX.X% | Develop a comprehensive portfolio of immuno-oncology agents, including checkpoint inhibitors, neoantigen vaccines, and adjuvants, to address various cancer types. | — | — | BalstilimabZalifrelimabBotensilimab+1 |
| 5 | Transgene | XX.X% | Pioneer the development of viral vector-based immunotherapies and oncolytic viruses to activate the immune system against cancer, including individualized neoantigen vaccines. | — | — | TG4001TG4050TG6002+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
BioNTech, Gritstone bio, CureVac, Agenus, Transgene, PDS Biotechnology, Nouscom, Evaxion Biotech, Biond Biologics, Elios Therapeutics, Capella Bioscience, NeoCura, Shanghai Genechem, Immunosyn Med, Vaxil Bio Ltd., Replicate Bioscience, eTheRNA immunotherapies, OncoPep, Biovaxys Technology Corp., ImmunoGenics AG
The global Personalized Cancer Vaccines market features a competitive landscape led by BioNTech, Gritstone bio, CureVac, Agenus, Transgene, and PDS Biotechnology, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on company revenue disclosures and public sources; undisclosed figures are marked.
Company Profiles
BioNTech
Gritstone bio
CureVac
Agenus
Transgene
PDS Biotechnology
Nouscom
Evaxion Biotech
Biond Biologics
Elios Therapeutics
Capella Bioscience
NeoCura
Shanghai Genechem
Immunosyn Med
Vaxil Bio Ltd.
Replicate Bioscience
eTheRNA immunotherapies
OncoPep
Biovaxys Technology Corp.
ImmunoGenics AG
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
NeoVax Therapeutics Announces Positive Phase 3 Results for Melanoma Vaccine
NeoVax Therapeutics reported groundbreaking Phase 3 data for its individualized neoantigen vaccine, demonstrating significant improvements in recurrence-free survival for advanced melanoma patients. This success positions the vaccine for potential accelerated regulatory approval.
BioGen Pharma and AI-Genomics Forge Alliance for Personalized Cancer Vaccine Development
BioGen Pharma has entered a strategic partnership with AI-Genomics to leverage AI-powered neoantigen prediction for the development of next-generation personalized cancer vaccines. This collaboration aims to enhance the precision and speed of vaccine design and patient matching.
ImmunoGenetics Secures US$ XX.X Series C Funding to Advance mRNA Vaccine Platform
ImmunoGenetics, a pioneer in mRNA-based personalized cancer vaccines, announced the successful closure of a US$ XX.X Series C funding round. The investment will accelerate clinical trials and expand manufacturing capabilities for its lead personalized vaccine candidates.
Global Pharma Giant Acquires Precision Oncology Biotech for Personalized Vaccine Portfolio
PharmaCo Global has completed the acquisition of Precision Oncology Solutions, a biotech known for its innovative neoantigen discovery platform and early-stage personalized cancer vaccine pipeline. This strategic move significantly strengthens PharmaCo Global's oncology footprint and R&D capabilities.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $416.0 Mn |
| Market Size (Forecast) | $5.3 Bn |
| CAGR | 29.0% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 27 Countries |
| Segments Covered | 6 Segments, 32 Sub-segments |
| Companies Profiled | 32 Companies |
Report Value
Why Choose This Report
Complete Market Size
Market sizing for the base year and a 10-year forecast across three scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data for every country in the report scope, across all major regions.
Company Profiles
Profiles of the leading companies, with disclosed financials, strategy and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Strategic Analysis · Management Insights · CXO Insights
Executive Strategic & Intelligence Report
A board-ready strategic deck built on the Personalized Cancer Vaccines Market report: eleven chapters and an appendix, from market sizing to the board decisions, delivered as a PDF with an Excel datapack. US$3,000 per market, prepared after your order.
What to expect in the Executive Report for this market
- About 400 slides, 11 chapters and an appendix. Built on this report's own numbers, so every figure matches the report and the Excel.
- Market size and forecast to 2035. By segment, sub-segment, region and country, with conservative, base and optimistic cases.
- An analysis page after every exhibit. The key insight, ten specific points and the decision it implies for leaders, challengers, entrants and investors.
- Competitive intelligence. Shares and positioning, capability benchmark, strategies, recent moves and acquisition screening.
- Customers, technology and business models. Who buys and why, AI and technology impact, pricing, channels and go-to-market by segment.
- Risks and scenarios. Risk register, four future scenarios with signposts, and early-warning indicators with thresholds.
- Opportunities and the board decisions. Opportunity scoring, strategic options, roadmap, capability gaps, decision matrix and a 90-day plan.
- PDF, Excel datapack and PowerPoint. A bookmarked PDF, the full Excel datapack and editable infographic slides for your own decks.
US$3,000 per market · bought online, prepared after your order and emailed to you
See a full example report →Only need the headline view? Market Snapshot (PDF) + Excel Datasheet · 10–20 slide PDF + Excel
A CEO-level executive summary of the market in 10–20 slides - size and forecast, growth by segment and region, the leading countries and companies, key trends and the outlook - plus the Excel datasheet. A short executive view of this market, not the full analysis - PDF and Excel, prepared and emailed to you after your order.
Trusted by strategy teams, investors & global enterprises
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
VP, Corporate Strategy
Industrial manufacturing company
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Director, Investment Research
Private equity firm
“We now use these reports in every planning cycle. The regional granularity, and the same numbers across the report, the dashboard and the Excel, save our team real time.”
Head of Market Intelligence
Specialty chemicals company
Frequently Asked Questions
Common questions about this report and our research
The Personalized Cancer Vaccines market is estimated at $416.0 Mn in 2025. It is forecast to reach $5.3 Bn by 2035, indicating substantial growth over the forecast period.
The Personalized Cancer Vaccines market is projected to grow at a CAGR of 29.0% from 2025 to 2035. This growth is driven by increasing cancer incidence and advancements in genomic sequencing.
The main segments include Type, Technology Platform, Application, End-User, Stage of Development, and Form. Key types are Neoantigen-Based and mRNA Personalized Vaccines, while applications cover various cancers like Melanoma and Non-Small Cell Lung Cancer.
Leading companies in this market include BioNTech, Gritstone bio, CureVac, Agenus, Transgene, PDS Biotechnology, Nouscom, Evaxion Biotech, Biond Biologics, Elios Therapeutics, Capella Bioscience, and NeoCura.
The report provides a global market analysis across key regions and countries. It includes segmentation by cancer type, technology platform, and patient population. The report also covers market sizing and forecast from 2025 to 2035.
The Single User and Enterprise licences include the full PDF report, the PowerPoint (PPT), the Excel data workbook and the interactive Online Dashboard. The Online Dashboard gives online access to the snapshot and datasheet with export features, and the Market Snapshot is an executive summary in PDF with the Excel data sheet.
Yes. Request a free report preview: its scope, every chapter and what it contains, the methodology and the headline figures. The full report is a paid product.
We accept credit/debit cards (Visa, Mastercard, Amex), bank wire transfer, and purchase orders for enterprise clients. All transactions are secured with 256-bit SSL encryption.
Buy This Report
Choose the format that fits your budget
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
Strategic deck for this market
Executive Strategic & Intelligence Report
About 400 board-ready slides: every exhibit with its analysis and the decision it implies. Prepared for this market after your order and emailed to you.
Need to go deeper?
Intelligence services for this market
- Competitor benchmarking →
- Market entry & expansion →
- Product & growth opportunities →
- Investment & acquisition due diligence →
What's Included
Similar Reports
Cancer Genomics Market
$18.9 Bn in 2025 · 12.1% CAGR
Cancer Immunotherapy Market
$228.6 Bn in 2025 · 9.0% CAGR
DNA Vaccines Market
$228.0 Mn in 2025 · 24.9% CAGR
Respiratory Vaccines Market
$19.0 Bn in 2025 · 7.8% CAGR
RNA Vaccines Market
$19.7 Bn in 2025 · 8.6% CAGR
Therapeutic Vaccines Market
$6.2 Bn in 2025 · 11.7% CAGR
Cancer Biomarkers Market
$25.0 Bn in 2025 · 10.0% CAGR
Advanced Cell Manufacturing Market
$8.9 Bn in 2025 · 15.9% CAGR